April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
The treatment showed promising hair regrowth in advanced-stage hair loss.
3 citations
,
September 2021 in “EClinicalMedicine” ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
July 2023 in “Journal of the American Academy of Dermatology” Clinical trials for alopecia areata need better inclusion and retention of patients of color.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
March 2023 in “JAAD case reports” Baricitinib may not always prevent relapse in alopecia areata.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
July 2018 in “International Journal of Research in Medical Sciences” Platelet rich plasma was slightly more effective than no treatment for hair loss in alopecia areata patients.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
May 2025 in “Journal of Nanobiotechnology” The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
February 2026 in “Clinical Cancer Research” The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.
September 2023 in “Journal of the American Academy of Dermatology” Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
July 2025 in “Journal of Investigative Dermatology” 114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
26 citations
,
January 2017 in “Journal of Clinical Pediatric Dentistry” Dental erosion is common in adolescents and is linked to diet and higher socioeconomic status.
11 citations
,
November 2013 in “Skin Pharmacology and Physiology” Azelaic Acid is effective and safe for treating adult female acne, with few side effects.